相关实验视频

Updated: Sep 15, 2025

Effects of Allogeneic Platelet-Rich Plasma PRP on the Healing Process of Sectioned Achilles Tendons of Rats: A Methodological Description

Effects of Allogeneic Platelet-Rich Plasma PRP on the Healing Process of Sectioned Achilles Tendons of Rats: A Methodological Description

Published on: March 19, 2018

减少/消除慢性神经病痛的机制,重点关注富血小板血

Damien P Kuffler¹, Christian A Foy²

¹Institute of Neurobiology, Medical School, University of Puerto Rico, San Juan, PR, United States.

Experimental biology and medicine (Maywood, N.J.)

|July 15, 2025

概括

外周神经创伤会导致慢性神经病痛. 新型富血小板血 (PRP) 配方通过解决潜在的原因,为消除疼痛提供了潜在的长期解决方案.

科学领域:

神经科学是一个神经科学.
再生医学是一种再生医学.
疼痛管理疼痛管理

背景情况:

周围神经创伤经常导致由于炎症和神经过激动性而导致慢性神经病痛.
目前的治疗方法,如药物和手术,提供有限的缓解,并没有解决疼痛的根本原因.
富血小板血 (PRP) 已经显示出缓解疼痛的希望,但新的配方可能会提供更显著和长期的益处.

研究的目的:

审查各种慢性神经病痛治疗方法的疗效,包括药物,再生性外围神经接口 (RPNI),向肌肉再内核 (TMR) 和富血小板血 (PRP).
检查关于一种新型PRP应用技术的最新临床数据,以长期减少或消除慢性神经病痛.
讨论这种新型PRP方法提高效率的基础机制.

主要方法:

关于神经病痛治疗现有研究的文献综述.
对最近临床数据的分析,重点关注一种新的富血小板血 (PRP) 应用.
对药物,RPNI,TMR和PRP的比较疗效评估.

主要成果:

药物药剂和当前的替代疗法对神经病痛提供了不完全的,通常是暂时的缓解.
富血小板血 (PRP) 的新型配方和应用技术已经证明了长期减少和消除疼痛的潜力.
这种先进的PRP方法在治疗慢性神经病痛方面似乎比传统方法更有效.

结论:

新型富血小板血 (PRP) 配方在治疗慢性神经病痛方面取得了重大进展.
与现有治疗方法相比,这种创新的PRP疗法可能会提供更完整和更持久的解决方案.
对新型PRP机制的进一步研究是有必要的,以优化其用于疼痛管理的应用.

关键词:

轴突再生的重生作用慢性神经病痛慢性神经病痛慢性神经病痛神经修复神经的修复消除疼痛消除疼痛的方法血小板丰富血是什么意思血小板血小板是

更多相关视频

Author Spotlight: Regenerative Peripheral Nerve Interface (RPNI) Surgery in Postamputation Pain Management

Author Spotlight: Regenerative Peripheral Nerve Interface (RPNI) Surgery in Postamputation Pain Management

Published on: March 15, 2024

Preparation, Procedures and Evaluation of Platelet-Rich Plasma Injection in the Treatment of Knee Osteoarthritis

Preparation, Procedures and Evaluation of Platelet-Rich Plasma Injection in the Treatment of Knee Osteoarthritis

Published on: January 4, 2019

相关概念视频

Formation of the Platelet Plug

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

Analgesia and Pain Management

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...

Nociception

Nociception

Nociception—the ability to feel pain—is essential for an organism’s survival and overall well-being. Noxious stimuli such as piercing pain from a sharp object, heat from an open flame, or contact with corrosive chemicals are first detected by sensory receptors, called nociceptors, located on nerve endings. Nociceptors express ion channels that convert noxious stimuli into electrical signals. When these signals reach the brain via sensory neurons, they are perceived as pain.

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...